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Bioavailability of diphenylhydantoin 
A four-way crossover study was performed in 8 adult volunteers using a Latin square 
design with 4 groups of 2 subiects arranged in order of increasing body weight. Single 
100 mg doses of diphenylhydantoin (DPH) sodium were administered as an aqueous solution 
(treatment A), the innovator's capsule (treatment B), alld a commercially available generic 
capsule (treatment D). A single 300 mg dose (treatment C) was also administered as three 
100 mg (innovator's) capsules. DPH capsules from both manufacturers gave plasma levels 
that were not significantly different at any sampling time. Although DPH follOWing treatment 
A was absorbed more rapidly, prodUCing higher initial plasma levels than treatments B 
and D, the areas under the curves for the three treatments were equivalent. The area under 
the curve for treatment C was also three times that for treatment B. Plasma DPH 
concentrations were related to the reciprocal of body weight, but plasma protein binding 
had no effect on the observed intersubiect variance in plasma levels. 
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Diphenylhydantoin (DPH) is an anti-
convulsant widely used in the prophylactic 
management of grand mal and psycho-
motor seizures. 4 Although DPH plasma 
levels have been correlated with dose, 
toxicity, and seizure control,16 the situation 
is complicated by dose-dependent kinet-
ics.1, G, 9 In addition, the physicochemical 
factors that influence the bioavailability 
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of DPH can dramatically affect both the 
rate and extent of its absorption. 7,10 In 
this context, significant differences in plas-
ma drug levels were observed by Martin 
and associates13 and Arnold and associates 2 
follOWing single doses of DPH obtained 
from different manufacturers. 
The present study was undertaken: (1) 
to compare plasma levels of DPH after oral 
administration of single 100 mg doses of 
diphenylhydantoin sodium as an aqueous 
solution, the innovator's capsule, and a 
commercially available generic capsule; 
and (2) to determine whether the dose de-
pendency exhibited by DPH influences its 
bioavailability in the therapeutic range of 
100 to 300 mg. 
727 
728 Albert el al. 
Table I. Dosage schedule and treatments 
Treatment 
Sub- Phase Phase I Phase I Phase 
iects Group I II III IV 
1,2 I A" Bt Dt C§ 
3,4 II B C A D 
5,6 III C D B A 
7,8 IV D A C B 
·Oral solution (100 mg): The contents of one Dilantin 
Kapseal, 100 mg (Parke, Davis & Co.), dissolved in a 
mixture composed of 10 ml of 95% ethanol, 35 ml of 
propylene glycol, 40 ml of pH 6.8 phosphate buffer (1 M 
in total phosphate), and 40 ml of Coca-Cola syrup, were 
swallowed; the container was rinsed with 120 ml of 
water and the rinsings were swallowed. 
fInnovator's capsule (100 mg): One Dilantin Kapseal, 
100 mg, was swallowed intact with 240 ml of water. 
tGeneric capsule (100 mg): One <liphenylhydantoin 
sodium capsule, 100 mg (distributed by Pharmacon Inc., 
Detroit) was swallowed intact with 240 ml of water. 
~Innovator's capsule (300 mg): Three Dilantin Kap-
seals, 100 mg each, were swallowed intact with 240 ml of 
water. 
Methods 
Protocol. Eight healthy adult male vol-
unteers between the ages of 21 and 40 and 
weighing between 70 and 95 kg, with 
normal vital signs and laboratory screen-
ing values, were selected. The study was 
performed using a Latin square design 
with 4 groups of 2 subjects, arranged in 
order of increasing body weight. Each 
subject received 3 single 100 mg doses and 
one single 300 mg dose of diphenylhydan-
toin sodium orally, 2 weeks apart accord-
ing to the dosage schedule shown in Table 
I. The subjects fasted from 10 hours prior 
to dosing until 4 hours post administration 
of the drug. 
Ten-milliliter blood samples were col-
lected in heparinized Vacutainers just prior 
to dosing and at 0.5, 1, 2, 4, 6, 8, 12, 24, 
48, 72, and 96 hours after dosing. The 
plasma was separated, frozen, and kept 
in a frozen state until just prior to as-
say. 
Analytical method. Two-milliliter plasma 
samples were assayed for unchanged DPH 
by the benzophenone procedure described 
by Dill and associates3 using the following 
modifications suggested by Saitoh and 
associates14: (1) benzophenone was formed 
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by oxidizing DPH with alkaline perman-
ganate for 10 minutes at 80°; (2) benzo-
phenone, which was extracted into 2.0 ml 
of spectrophotometric grade n-heptane 
(Matheson, Coleman, and Bell, Norwood), 
was measured at 247 nm in 10 mm micro-
cells using an approximately expanded 
scale (0 to 0.1 or 0 to 0.5 absorbance units 
full-scale deHection) of a spectrophotom-
eter (Gilford Model 2400 spectrophotom-
eter, Gilford Instrument Laboratories, Inc., 
Oberlin). 
Plasma protein binding. One-milliliter 
portions of drug-free plasma and plasma 
samples from treatment C (see Table VI) 
for each subject were incubated for 30 
minutes at 25° C with 10 fLI of 14C-Iabeled 
DPH (New England Nuclear Corp., Bos-
ton; specific activity, 5.21 mCi/mM) using 
a methanolic stock solution, 4.88 fLg/ml. 
Ultrafiltration of the plasma samples was 
performed at 25° C in membrane cones 
( centriHo CF -50 membrane ultrafilter; 
Amicon Corp., Lexington), which were 
soaked in deionized water at least 1 hour 
before use. After removing residual water 
by centrifuging at 1,000 g for 5 minutes 0.9 
ml of plasma was pipetted into the cone 
and then centrifuged at 800 g for 30 min-
utes. At the end of the centrifugation, 100 
fLl aliquots of ultrafiltrate were removed 
for scintillation counting (Packard Tri-
Carb Liquid Scintillation Spectrometer, 
Packard Instrument Co., Inc., Downers 
Grove) in vials containing 15 ml of Unogel 
(Schwarz/Mann Co., Orangeburg). A 100 
fLl portion of plasma was also analyzed for 
radioactivity prior to centrifugation. The 
fraction unbound was calculated as the 
quotient of the radioactivity in the ultra-
filtrate and in the plasma before ultra-
filtration. 
Statistical analysis. Plasma concentra-
tions at each sampling time, peak plasma 
concentrations and times of their occur-
rence, and areas were analyzed by analysis 
of variance for crossover design. The 
sources of variation in this type of analysis 
are groups, subjects within a group, time 
periods, treatments, and residual. 
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Fig. 1. DPH plasma concentration, time data in Subjects 1 to 4 following 4 oral treatments: 
treatment A from time of peak to 96 hr; treatments B, C, and D from 6 hr to 96 hr. Inserts 
show expanded 0 to 6 hr data .• - - - - -., Treatment A. • ., Treatment B. 
o 0, Treatment C. +- - - -+, Treatment D. 
Results 
Comparison of treatments. Figs. 1 and 2 
graphically depict DPH plasma concentra-
tion, time data in 8 subjects following the 
4 oral treatments, while Table II and Fig. 
3 summarize the averages at each of 11 
sampling times post administration of the 
drug. The analysis of variance and multi-
ple-range tests for comparing averages of 
pairs of treatments"' 1" are presented in 
Table III. The pharmacokinetic parameters 
derived from the plasma level data appear 
in Table IV, while Table V reports the 
corresponding statistical analyses. 
Analysis of variance for crossover design 
indicated that the differences among treat-
ment averages were highly Significant at 
all sampling times except 96 hours (Tables 
II and III). Differences among treatment 
average peak plasma concentrations of 
DPH, the times of their occurrence, and 
treatment average areas under the plasma 
curves were also highly significant (Tables 
IV and V). 
Multiple-range tests indicated that aver-
age plasma concentrations of DPH fol-
lowing treatments A and B differed sig-
nificantly at 0.5, 1, 2, and 4 hours post-
730 Albert el al. 
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Fig. 2. DPH plasma concentration time data in Subjects 5 to 8 following 4 oral treatments: 
treatment A from time of peak to 96 hr; treatments B, C, and D from 6 hr to 96 hr. Inserts 
show expanded 0 to 6 hr..data. See Fig. 1 for further explanation. 
administration of drug, suggesting that 
DPH in solution given orally (treatment 
A) was more rapidly absorbed than DPH 
formulated as the innovator's capsule 
(treatment B). Tables IV and V support 
this by showing that the differences be-
tween mean times of individual subjects 
to attain peak concentrations were signifi-
cant. These results are clearly illustrated 
in Figs. 1 to 3. On the other hand, since 
no significant differences in average areas 
under the plasma curves following treat-
ments A and B occurred, their bioavail-
abilities were considered to be equivalent. 
Tables II through V also show that the 
generic 100 mg capsule (treatment D) 
was bioequivalent to the innovator's 100 
mg capsule (treatment B) because there 
were no significant differences between 
treatment means at any sampling time 
and average areas under the plasma 
curves. 
Fig. 4 compares average areas (0 to 96 
hours) following the 4 treatments. The 
lines at the top of the bars mark off plus 
and minus one standard deviation of the 
mean in each case. It is apparent from the 
figure and the data in Table IV that the 
area following administration of three 100 
mg capsules (h'eatment C) was three times 
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the area following administration of a 
single 100 mg capsule (treatment B). 
Other sources of variation. No significant 
differences were observed among time 
periods following the four treatments. 
However, significant differences (p ~ 0.05) 
were found between groups 1 and 4 at 6, 
8, 12, and 24 hours post administration of 
drug and in areas under the plasma con-
centration time curves. This suggested that 
the plasma DPH differences could be re-
lated to the reciprocal of body weight as 
would be expected if the volume of dis-
tribution of DPH was directly proportional 
to body weight. 
The regression equation for a plot of 
area against mg/kg dose is: y = 37.2x -
0.544 with r = 0.824. The intercept did 
not differ significantly from zero. If Sub-
ject 1 was not included in the linear re-
gression, then 75% of the variance in area 
among subjects could be accounted for 
in terms of mg/kg dose. 
Plasma protein binding. Table VI shows 
the per cent unbound DPH for each sub-
ject at two concentrations. Since the frac-
tion unbound appeared to be independent 
of concentration in the range of plasma 
drug levels observed in this study, a direct 
comparison of total plasma concentrations 
to assess bioavailability was justified. The 
values in Table VI compare favorably with 
those reported previously.12 
Discussion 
Influence of physicochemical factors. The 
effects of dosage from variables on thera-
peutic efficacy or bioavailability will be 
manifest principally in differences in rate 
of absorption or differences in efficiency of 
absorption. Significant differences were 
shown in time of peak and peak plasma 
concentration of DPH following treatments 
A and B, indicating that DPH in solution 
given orally was more rapidly absorbed 
than drug formulated as the innovator's 
capsule. On the other hand, since no sig-
nificant differences were shown in areas 
following the two treatments, the drug in 
capsule form was fully available relative 
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Table II. Average DPH plasma 
concentrations and their corresponding 
coefficients of variation in per cent for 
the 8 normal subjects 
Mean plasma levels (p.g/ml) and 
coefficients of variation (%) 
Time Treat- I Treat- I Treat- I Treat-
(hr) ment Ament B ment C ment D 
0.5 1.5S O.lS 0.37 0.31 
(3S.4) " ( 116) (121) (SO.3) 
1 2.33 0.74 1.35 1.03 
(17.1) (67.4) (69.6) (41.6 ) 
2 2.1S 1.07 2.60 1.46 
( 17.2) (37.7) (44.2) (25.6) 
4 l.S7 1.25 3.03 1.66 
(26.6) (27.4) (26.1) ( 17.5) 
6 1.65 1.32 3.27 1.62 
(22.7) (2S.1) (23.5) (19.7) 
S 1.45 1.23 3.32 1.44 
(27.9) (24.3) (2S.1) (19.1 ) 
12 1.13 1.20 3.17 1.17 
(30.S) (42.3) (24.9) (2S.2) 
24 0.64 0.73 2.47 0.65 
( 41.0) (55.S) (37.1 ) (33.1) 
4S 0.21 0.38 1.06 0.20 
(S1.0) ( 109) (51.4 ) (S2.4) 
72 0.13 0.14 0.31 0.06 
( 112) ( 14S) (SO.7) ( 125) 
96 0.05 0.05 0.10 0.01 
( 150) (102) ( 13S) ( 175) 
"Bracketed values are coefficients of variation of the 
means, in per cent, i.e. (standard deviation/mean) x 100. 
to the drug in solution. From a therapeutic 
point of view, the complete availability of 
DPH from the innovator's capsule is note-
worthy because the drug is given several 
times a day for prolonged periods. Rapid 
absorption is probably less important, and, 
in fact, may be undesirable because of side 
effects due to either high initial blood 
levels of DPH or adverse reaction to the 
vehicle itself. Nausea and diarrhea were 
two common side effects following admin-
istration of drug in solution that were ab-
sent following the three other treatments. 
The innovator's 100 mg capsule (treat-
ment B) and the generic 100 mg cap-
sule ( treatment D) were found to be 
bioequivalent, indicating that formulation 
differences had no effect on bioavailability 
for the two products tested. Similar re-
sults were reported by Glazko,7 who found 
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Fig. 3. Average DPH plasma levels for 8 subjects following 4 oral treatments. Insert shows 
expanded 0 to 6 hr data. See Fig. 1 for further explanation. 
Table III. Results of analyses of variance and multiple-range tests for comparison 
of average plasma levels of diphenylhydantoin 
Time (hr) 
0.5 
1 
2 
4 
6 
8 
12 
24 
48 
72 
96 
C.V." (%) 
63.2 
42.0 
38.1 
22.7 
17.4 
21.3 
19.8 
35.4 
61.5 
79.9 
123 
Significance level 
Among treatments A, B, C, I Between treatments I Between treatments 
and D A and B Band D 
p < 0.001 P ~ 0.05 N.S.t 
p < 0.001 p ~ 0.05 N.S. 
0.001 < p < 0.005 p ~ 0.05 N.S. 
P < 0.001 P ~ 0.05t N.S. 
p < 0.001 N.S. N.S. 
P < 0.001 N.S. N.S. 
P < 0.001 N.S. N.S. 
P < 0.001 N.S. N.S. 
P < 0.001 N.S. N.S. 
0.001 < p < 0.005 N.S. N.S. 
N.S. N.S. N.S. 
°Coefficient of variation, in per cent, from the residual mean square of the analysis of variance. 
t Not significant. 
l Borderline level of significance. 
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Table IV. Pharmacokinetic parameters derived from DPH plasma concentration, 
time data, and their corresponding coefficients of variation 
Parameter value and coefficient of variation (%) 
733 
Parameter Treatment A I Treatment B I Treatment C Treatment D 
Peak plasma concentration (",g/ml) 2.42 1.48 3.52 1.80 
(14.3)" (29.3) (25.4) ( 15.0) 
Time of peak (hr) 1.63 6.63 6.00 4.50 
(65.3) (63.0) (56.3) (46.0) 
Area ~96 hr (",g/ml x hr) 46.5 47.0 132 41.3 
(38.3) (58.3) (36.8) (32.3) 
Area O~OO (",g/ml x hr) 49.1 49.2 134 41.8 
(40.8) (57.5) (38.5) (32.6) 
"Bracketed values are coefficients of variation of the means, in per cent, i.e. (standard deviation/mean) x 100. 
Table V. Results of analyses of variance and multiple-range tests for comparison 
of pharmacokinetic parameters derived from DPH plasma levels 
Parameter 
Peak plasma level 
Time of peak 
Area ~oo 
Area ~96 hr 
C.V. (%)" 
21.3 
50.5 
32.0 
33.8 
Among treatments I 
A, B, C, and D 
p < 0.001 
0.001 < p < 0.005 
P < 0.001 
P < 0.001 
Significance level 
Between treatments I Between treatments 
A and B Band D 
p ::; 0.05 N.S.t 
p ::; 0.05 N.S. 
N.S. N.S. 
N.S. N.S. 
"Coefficient of variation in per cent from the residual mean square of the analysis of variance. 
t Not significant. 
Table VI. Plasma protein binding of DPH using sub;ect plasma from treatment C 
Sub;ect Wt (kg) DPH (",glml) % unbound Sub;ect average 
1 70.5 0.0488 5.7 5.7 
3.57 (12 hr) 5.7 
2 71.8 0.0488 8.8 8.4 
3.47 ( 8 hr) 7.9 
3 72.3 0.0488 7.6 7.5 
4.58 ( 8 hr) 7.3 
4 76.8 0.0488 5.9 5.5 
2.19 ( 2 hr) 5.1 
5 79.1 0.0488 6.6 6.6 
3.23 (12 hr) 6.5 
6 81.8 0.0488 6.4 6.7 
3.23 ( 8 hr) 6.9 
7 81.8 0.0488 7.2 7.9 
2.28 ( 8 hr) 8.7 
8 95.5 0.0488 6.0 6.3 
2.99 ( 8 hr) 6.5 
Mean 6.8 
S.D. 1.1 
that DPH capsules from four different 
manufacturers gave plasma levels that 
were not significantly different. However, 
bioequivalence needs to be demonstrated 
for each manufacturer's formulation. The 
results reported herein do not imply that 
other DPH capsules, made by the same or 
different manufacturers, will provide satis-
factory results in man. DPH following 
treatments Band D also appeared to be 
released from their respective capsules 
nonuniformly as evidenced by the non-
734 Albert el al. 
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Fig. 4. Comparison of average areas under DPH plasma concentration time curves for 8 
subjects given 4 different treatments. The lines mark off :t 1 standard deviation of the mean 
in each case. 
continuous appearance of the individual 
plasma curves (inserts of Figs. 1 and 2) 
from zero time to 6 hours postadministra-
tion of drug. This effect, which was absent 
for the corresponding time interval fol-
lowing administration of DPH in solution 
(except for Subject 5), has not been re-
ported formerly. 
Influence of physiological and biochem-
ical factors. Figs. 1 to 3 reveal evidence 
for three distinct factors that may in-
fluence the absorption, distribution, and 
elimination of DPH in man. These factors 
are (1) lag time for absorption, (2) bile 
cycling, and (3) saturation kinetics. 
The individual plasma curves (inserts of 
Figs. 1 and 2) suggest a lag time for ab-
sorption of DPH following treatments B, 
C, and D. This may be due to dissolution 
of the drug from the capsule and gastric 
emptying since DPH is mainly absorbed 
from the intestinal tract. 
Evidence for enterohepatic (bile) cy-
cling is provided by what appears to be 
an additional absorptive component in the 
plasma curve during distribution or elimi-
nation. The effect is parl:icularly pro-
nounced in Subjects 1, 3, and 6. Although 
bile cycling of DPH may be implicated 
in the metabolic disposition of the drug,r, 8 
inference of its existence from our data is 
speculative. 
The nonlinear elimination characteristics 
of DPH are exemplified in Figs. 1, 2, and 
3 by the characteristic "hockey-stick" shape 
of the plasma curves following treatment 
C (300 mg dose). Large errors in bio-
availability estimates can sometimes be 
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made for drugs such as DPH, which ex-
hibit saturation-kinetics because the dose/ 
area ratio is dose-dependent (i.e., plasma 
clearance is not constant). However, this 
study clearly shows a linear relationship 
between area and dose of DPH in the 
therapeutic range of 100 to 300 mg (Fig. 
4). Similar results have been reported by 
Glazk07 in the 200 to 400 mg range. 
Influence of plasma protein binding. 
Jahnchen and Levy" have suggested that 
the intersubject variability associated with 
many pharmacokinetic parameters may be 
related to intersubject differences in plas-
ma protein binding. This hypothesis with 
DPH in man was tested by plotting area 
against (D /W) (1/ (J') where D /W is the 
mg/kg dose and (J' is the fraction of drug 
unbound. When the correlation coefficient 
was compared against that for area against 
D /W, there was no improvement (0.80 
and 0.82). Hence, plasma protein binding 
probably exerted little if any influence on 
the intersubject variability observed in the 
areas. 
Pharmacokinetic implications. Previous 
investigations by others7.~, 10, 17 and this 
report suggest that DPH is susceptible to 
enterohepatic cycling. In addition, there 
appears to be a lag time and nonuniform 
input kinetics when capsules are adminis-
tered. Hence, elaboration of a pharmaco-
kinetic model, which ignores these con-
siderations, may be tenuous. 
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